Newsfeeds Archive - Page 4 of 4

1 minute read

Xencor Q4 EPS $(0.20) Beats $(0.79) Estimate, Sales $21.61M Beat $20.06M Estimate

February 23, 5:03 PM

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.79) by 74.68 percent. This is a 116.53 percent decrease over earnings of $1.21 per share from the same

XNCR

17 minute read

Earnings

Earnings Scheduled For February 23, 2023

By Benzinga Insights

February 23, 6:18 AM

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

AAOI

1 minute read

EF Hutton Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $42

By Benzinga Newsdesk

January 31, 5:36 AM

EF Hutton analyst Michael King initiates coverage on Xencor (NASDAQ:XNCR) with a Buy rating and announces Price Target of $42.

XNCR

1 minute read

EF Hutton Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $42

By Benzinga Newsdesk

January 30, 8:03 AM

EF Hutton analyst Michael King initiates coverage on Xencor (NASDAQ:XNCR) with a Buy rating and announces Price Target of $42.

XNCR

3 minute read

Xencor Presents Data From Phase 1 Study Of Plamotamab In Relapsed Or Refractory Non-Hodgkin Lymphoma At The American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

December 12, 11:09 AM

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from

XNCR

1 minute read

RBC Capital Maintains Outperform on Xencor, Lowers Price Target to $36

By Benzinga Newsdesk

November 8, 8:15 AM

RBC Capital analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $40 to $36.

XNCR

13 minute read

Earnings

Earnings Scheduled For November 7, 2022

By Benzinga Insights

November 7, 4:59 AM

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

AAON

1 minute read

JP Morgan Initiates Coverage On Xencor with Overweight Rating, Announces Price Target of $37

By Benzinga Newsdesk

Today, 7:41 AM

JP Morgan analyst Brian Cheng initiates coverage on Xencor (NASDAQ:XNCR) with a Overweight rating and announces Price Target of $37.

XNCR

2 minute read

Earnings

Xencor’s Return On Capital Employed Overview

By Benzinga Insights

August 11, 11:13 AM

XNCR

2 minute read

Caris Life Sciences and Xencor Entered Target Discovery Collaboration and License Agreement for Novel XmAb Bispecific Antibodies; Caris to Receive Upfront Payment and Be Eligible to Receive Up to ~$120M in License Fees, Discovery, Development, Regulato…

By Charles Gross

August 2, 6:43 AM

Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and

XNCR